Atossa Genetics (ATOS) Upgraded to “Strong-Buy” by ValuEngine

Atossa Genetics (NASDAQ:ATOS) was upgraded by investment analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Friday.

Separately, Maxim Group reiterated a “buy” rating and issued a $5.00 price target on shares of Atossa Genetics in a research note on Wednesday, January 9th.

Shares of ATOS stock opened at $7.07 on Friday. Atossa Genetics has a fifty-two week low of $0.80 and a fifty-two week high of $7.56.

An institutional investor recently raised its position in Atossa Genetics stock. Virtu Financial LLC raised its position in Atossa Genetics Inc (NASDAQ:ATOS) by 405.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 69,903 shares of the company’s stock after acquiring an additional 56,064 shares during the quarter. Virtu Financial LLC owned approximately 1.24% of Atossa Genetics worth $71,000 as of its most recent SEC filing. 13.87% of the stock is currently owned by hedge funds and other institutional investors.

Atossa Genetics Company Profile

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Read More: What economic reports are most valuable to investors?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit